MALIGNANT SOLID TUMOR
Clinical trials for MALIGNANT SOLID TUMOR explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT SOLID TUMOR trials appear
Sign up with your email to follow new studies for MALIGNANT SOLID TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New injection fights Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called tolododekin alfa (ANK-101) in people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumors to see if it is safe and tolerable. About 97 adults with various cancers, inclu…
Matched conditions: MALIGNANT SOLID TUMOR
Phase: PHASE1 • Sponsor: Ankyra Therapeutics, Inc • Aim: Disease control
Last updated May 26, 2026 11:26 UTC
-
New study matches cancer drugs to tumor DNA for better results
Disease control Recruiting nowThis study tests cancer treatments that target specific genetic changes in tumors. It includes 455 adults with advanced solid tumors that have not responded to standard therapies. Participants receive a treatment chosen based on their tumor's molecular profile, and the study aims…
Matched conditions: MALIGNANT SOLID TUMOR
Phase: PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated May 26, 2026 11:25 UTC
-
New drug cocktail offers hope for kids with rare cancers
Disease control Recruiting nowThis study tests a combination of four drugs (cyclophosphamide, sorafenib, bevacizumab, and atezolizumab) in children and young adults with relapsed or hard-to-treat solid tumors. The goal is to find safe doses and see if the treatment shrinks tumors. The trial has two parts: fir…
Matched conditions: MALIGNANT SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 26, 2026 11:24 UTC
-
New hope for advanced cancer patients as FH-006 trial begins
Disease control Recruiting nowThis study tests a new drug called FH-006 in 200 women aged 18-75 with advanced solid tumors that have worsened after standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. Participants will be closely monitored for side effects and immune…
Matched conditions: MALIGNANT SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 11:08 UTC
-
New hope for Hard-to-Treat cancers: first human trial of targeted drug begins
Disease control Recruiting nowThis study tests a new drug, ifinatamab deruxtecan, in people with advanced solid tumors that have not been cured by other treatments. It is the first time this drug is being used in humans. The study has two parts: first, to find the safest dose, and second, to see how well the …
Matched conditions: MALIGNANT SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated May 18, 2026 12:02 UTC
-
New PET tracer could reveal if immunotherapy is working
Diagnosis Recruiting nowThis study is testing a new imaging agent (GEH200520/GEH200521) that uses a PET scan to take pictures of solid tumors. In the first part, researchers check the safety of the agent in 50 adults with advanced cancer. In the second part, they use the agent to see if tumors change af…
Matched conditions: MALIGNANT SOLID TUMOR
Phase: PHASE1 • Sponsor: GE Healthcare • Aim: Diagnosis
Last updated May 12, 2026 13:40 UTC
-
Massive canadian study hunts rare cancer mutations for better treatments
Knowledge-focused Recruiting nowThis study follows 5,500 Canadian cancer patients whose tumors have rare genetic changes. Researchers will collect data on how these cancers behave and how well different treatments work, including newer targeted drugs. The goal is to learn more about these uncommon mutations to …
Matched conditions: MALIGNANT SOLID TUMOR
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated May 22, 2026 13:51 UTC